We read with interest the articles by Estella Ektorp1 and Nathan Peiffer-Smadja and colleagues,2 which reported receipt of death threats and cyber harassment in Brazil, France, and Switzerland after publication of studies that did not demonstrate clinical efficacy for chloroquine and hydroxychloroquine in COVID-19.